. 2019 Sep 17;3:100042. doi: 10.1016/j.jvacx.2019.100042

Table 2.

Pooled adjusted seasonal vaccine effectiveness against influenza A(H1N1)pdm09 and A(H3N2), overall, by age groups and by vaccine type, previous vaccination and time within the season. I-MOVE/I-MOVE+ primary care multicenter study, Europe, influenza seasons 2016–17 and 2017–18.

Influenza A(H3N2) 2016–17
Age group	Population	N^a	Cases; vacc /Controls; vacc^b	Adjusted VE (%)	95% CI (%)
All ages		10,591	4733;516/5858;680	28	17–38
0–14 years		3452	1494;46/1958;66	28	−10 to 53
15–64 years		5840	2606;183/3234;286	34	18–46
≥65 years		1298	633;287/665;328	15	−10 to 34
All ages	Target group for vaccination	3181	1440;431/1741;543	22	7–34
All ages	Subunit vaccine^a	8304	3832;179/4472;238	31	13–46
	Split virion vaccine^a	9303	4209;188/5094;220	23	4–39
	Adjuvanted vaccine^a	4678	2027;32/2651;48	49	12–71

≥9 years	Unvaccinated	7822	3168/3343^b	Ref
	2016–17 vaccine only		69/132^b	50	32–63
	2015–16 vaccine only		87/144^b	29	5–47
	2015–16 and 2016–17 vaccines		412/467^b	20	5–32

All ages	Oct-Dec	3541	1442;141/2099;206	38	16–54
	Jan	4379	2389;260/1990;289	34	18–47
	Feb-April	2671	902;115/1769;185	1	−34 to 27

Influenza A(H3N2) 2017–18

Age group	Population	N	Cases; vacc /Controls; vacc	Adjusted VE (%)	CI (%)

All ages		5607	731;119/4876;623	13	−15 to 34
0–14 years		1772	160;6/1612;74	29	−87 to 73
15–64 years		3128	444;33/2684;245	33	−3 to 56
≥65 years		673	127;80/546;283	−9	−74 to 32
All ages	Target group	1763	251;106/1512;512	13	−21 to 38
All ages	Subunit vaccine ^a	4556	471;56/3739;290	−3	−50 to 30
	Split virion vaccine ^a	4637	555;36/3906;140	19	−29 to 49

≥9 years	Unvaccinated	4051	491/2783^b
	17–18 vaccine only		11/105^b	49	1–74
	16–17 vaccine only		17/119^b	16	−47 to 52
	16–17 and 17–18 vaccines		95/430^b	7	−29 to 33

All ages	Oct-Dec	1413	138;19/1275;133	11	−72 to 54
	Jan	1849	230;42/1619;234	5	−54 to 41
	Feb-April	2345	363;58/1982;256	18	−24 to 45

Influenza A(H1N1)pdm09 2017–18

Age group	Population	N	Cases; vacc /Controls; vacc	Adjusted VE (%)	CI (%)

All ages		7175	1875;81/5300;643	59	47–69
0–14 years		2680	888;18/1792;80	64	37–79
15–64 years		3806	893;37/2913;256	50	28–66
≥65 years		684	94;26/590;307	66	42–80
15–37 years		1609	339;4/1270;54	71	18 to 90
38–52 years		1311	369;18/942;70	23	−38 to 57
53+years		1572	279;41/1293;439	64	47 to 76
All ages	Target group	2075	424;65/1651;526	56	40–68
All ages	Subunit vaccine ^a	6268	1745;39/4192;292	59	40–71
	Split virion vaccine ^a	6184	1745;11/4288;140	71	45–85

≥9 years	Unvaccinated	4784	981/3023^b
	17–18 vaccine only		6/110^b	79	51–91
	16–17 vaccine only		25/137^b	24	−22 to 52
	16–17 and 17–18 vaccines		61/441^b	46	26–61

All ages	Oct-Dec	2009	326;4/1683;152	87	62–95
	Jan	2277	673;33/1604;230	53	27–69
	Feb-April	2826	856;44/1970;257	53	32–67

CI: confidence interval; vacc: vaccinated; VE: vaccine effectiveness.

Among study sites where this vaccine type was used. Subunit and split virion vaccine refers to egg-propagated inactivated trivalent subunit and split virion vaccines, respectively. For adjuvanted vaccine only study sites using the MF59 adjuvant included.

Cases/controls.